Market closed
Mirum Pharmaceuticals/$MIRM
Mirum Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 2025 results and raised its 2025 revenue guidance.
9 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Ticker
$MIRM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
322
Website
MIRM Metrics
BasicAdvanced
$2B
-
-$1.85
0.96
-
Price and volume
Market cap
$2B
Beta
0.96
52-week high
$54.23
52-week low
$23.83
Average daily volume
429K
Financial strength
Current ratio
3.104
Quick ratio
2.834
Long term debt to equity
140.07
Total debt to equity
140.827
Interest coverage (TTM)
-6.12%
Management effectiveness
Return on assets (TTM)
-8.31%
Return on equity (TTM)
-37.08%
Valuation
Price to revenue (TTM)
5.815
Price to book
8.83
Price to tangible book (TTM)
-82.41
Price to free cash flow (TTM)
-183.623
Growth
Revenue change (TTM)
80.76%
Earnings per share change (TTM)
-53.74%
3-year revenue growth (CAGR)
160.13%
3-year earnings per share growth (CAGR)
-12.58%
What the Analysts think about MIRM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
MIRM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MIRM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MIRM News
AllArticlesVideos
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript
Seeking Alpha·1 day ago
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities
Seeking Alpha·4 days ago
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mirum Pharmaceuticals stock?
Mirum Pharmaceuticals (MIRM) has a market cap of $2B as of May 09, 2025.
What is the P/E ratio for Mirum Pharmaceuticals stock?
The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of May 09, 2025.
Does Mirum Pharmaceuticals stock pay dividends?
No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Mirum Pharmaceuticals dividend payment date?
Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.
What is the beta indicator for Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.